PMS12 Effectiveness of Allopurinol In Achieving And Sustaining Target Serum Urate: An Analysis of A National Integrated U.S. Healthcare System  by Singh, Ja & Yang, S
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A635
PMS10
Efficacy of Surgical VS. NoN-Surgical TrEaTMENT of carPal TuNNEl 
SyNdroME (cTS): a SySTEMaTic rEViEw
Goyal R, Kaneria J, Rai MK, Bhutani MK, Singh R, Rana P
Tata Consultancy Services, Mumbai, India
Objectives: To conduct a systematic review to compare the efficacy of surgical 
versus non-surgical treatment of carpal tunnel syndrome (CTS). MethOds: We 
searched Embase, Medline & Cochrane databases from January 2000 to June 2015 
and included all randomised controlled trials comparing any surgical versus non-
surgical therapies in patients with CTS. Two authors independently assessed the 
eligibility of the trials and performed all the necessary steps of a systematic review. 
A qualitative analysis of the results was done. Results: From the 112 studies 
retrieved, five studies reached the stage of data extraction. Three studies compared 
decompressive surgery with local steroid injection, one study compared surgical 
versus non-surgical (hand therapy and ultrasound) and the last study compared 
surgery versus splinting, respectively. The studies included 95 wrists, 163 wrists, 50 
patients, 116 patients and 176 patients. The study with 50 patients reported that at 
20 weeks patients who underwent surgery had greater symptomatic improvement 
than those who were injected with steroids. The mean improvement in GSS after 20 
weeks was 24.2 (SD 11.0) in the surgery group vs 8.7 (SD 13.0) in the injection group 
(p < 0.001). Similarly, the other two trials comparing surgery with steroid injection 
reported that surgery has additional benefits in improving CTS. The trial comparing 
surgery with splinting reported a success rate of 90% with surgery as compared to 
75% with splinting. The trial with surgery versus non-surgery revealed a signifi-
cant 12-month adjusted advantage for surgery in function (CTSAQ function score: 
Delta -0.40, 95% CI 0.11-0.70, p= 0.0081) and symptoms (CTSAQ symptom score: 0.34, 
0.02-0.65, p= 0.0357). cOnclusiOns: Surgical treatment of CTS relieves symptoms 
significantly better compared to non-surgical treatment. Further, the surgical treat-
ment was a better option as compared to local steroid injections and splinting.
PMS11
uSiNg acTiVE TEchNiquES To haNdlE chroNic low Back PaiN cauSEd By 
SEdENTary work
Gombos G1, Vizsy M1, Sió E1, Bajsz V1, Steinhausz V1, Szabó J1, Boncz I2, Schmidt B1
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary
Objectives: Chronic low back pain (cLBP) is a key issue for health care and society. 
The purpose of this study was to evaluate the efficacy of a 3-months long training 
programme by examining the muscular strength, the range of motion, the muscle-
stretching, the pain and the functional development at sedentary workers with 
cLBP. MethOds: The examination was carried out in Zalaegerszeg in 2014. Thirty 
patients were involved (30-60y) who had cLBP because of sedentary work for many 
years. The participants received core stability training and traditional active and 
passive stretching exercises integrated with myofascial release technique. Data 
collection: 1) core strength and stability tests (DAVID 110,130 and modified plank-
tests), 2) lumbar spine range of motion (Zebris-system), 3) muscle stretching (David-
conception), 4) pain and functionality (Visual Analog Scale, Roland-Morris Scale) 
and 5) general health status (physical examination, discharge report, self-made 
questionnaire). Descriptive statistics, t-test and chi2–test were used (IBM SPSS 
19v.). Results: The trunk muscle forces (flexors p= 0.003, extensors p= 0.008) and 
the modified plank tests (prone and side position p= 0.001, supine position p= 0.042) 
shown significant improvement. The spine range of motion shown significant 
improvements (p= 0.001). The level of pain decreased significantly (p= 0.001), simi-
lar to the Roland-Morris Index (p= 0.001). The muscle stretching tests represented 
important but not significant changes. cOnclusiOns: Present study provides 
further evidence of the effectiveness of core stabilisation and muscle stretching 
techniques in cLBP. It would be worthwhile to continue this study involving more 
patients with long follow-up emphasizing the myofascial release techniques.
PMS12
EffEcTiVENESS of alloPuriNol iN achiEViNg aNd SuSTaiNiNg TargET 
SEruM uraTE: aN aNalySiS of a NaTioNal iNTEgraTEd u.S. hEalThcarE 
SySTEM
Singh Ja, Yang S
UAB SCHOOL OF MEDICINE, Birmingham, AL, USA
Objectives: To comprehensively assess as to which patient, comorbidity, physi-
cian, system, health care access and disease factors are associated with the abil-
ity to achieve and maintain target serum urate (sUA) with allopurinol in patients 
with gout. MethOds: We used National VA national databases from 2002-2012. 
Patients were eligible if they had ≥ 2 outpatient or ≥ 1 inpatient encounters with 
an International Classification of Diseases-ninth version (ICD-9) code 274.xx for 
gout, and met 12-month observability rule. Index allopurinol use was defined as 
the filling of a new allopurinol prescription with no allopurinol exposure in the 
previous 121 days. Treatment successes were defined as the achievement of: (1) post-
index sUA < 6 mg/dl; and (2) post-index sUA < 6 mg/dl that was sustained. Results: 
41,153 unique patients with 47,072 episodes contributed to analyses of achieving 
target sUA (success 1) and 17,402 unique patients with 18,323 episodes to achiev-
ing and maintaining target sUA (success 2). In multivariable-adjusted models, the 
following were associated with significantly higher odds of both successes 1 and 
2: older age, normal BMI (18.5-25 kg/m2), currently married, Deyo-Charlson index 
score of 0, main provider being a physician, rheumatologist as the main provider 
rather than non-rheumatologist, Midwest location for the health care facility, a 
lower hospital bed size, service-connection conditions of 50% or more, longer dis-
tance to the nearest VA facility, lower pre-index sUA, higher allopurinol start and 
end dose, higher allopurinol adherence and recommended or fast allopurinol dose 
escalation. cOnclusiOns: In this study, we identified several important factors 
associated with achieving and maintaining sUA < 6 mg/dl. This new knowledge 
provides several new potential modifiable targets for improving the ability to lower 
serum urate with allopurinol pharmacotherapy and sustain a therapeutic target in 
patients with gout.
PMS7
rEducTioN iN c-rEacTiVE ProTEiN wiTh Biologic drugS iN rhEuMaToid 
arThriTiS aNd SPoNdyliTiS PaTiENTS iN gErMaN rhEuMaTologiST 
PracTicES
Gossen N, Kostev K
IMS Health, Frankfurt am Main, Germany
Objectives: C-reactive protein (CRP) is one of the markers of inflammation 
in the body and a predictor of treatment outcome in patients with rheumatoid 
arthritis (RA) treated with biologic drugs. CRP levels > 10 mg/L are associated 
with very high cardiovascular risk. The aim of this study was to evaluate the 
difference in mean CRP levels before and after the initiation of biologic drugs in 
German rheumatologist practices. MethOds: German Disease Analyzer database 
including 34 rheumatologist practices was used. Data from 1,695 patients (mean 
age 52.1 years, 62% female) with a diagnosis of either rheumatoid arthritis (RA, 
ICD 10: M05, M06) or spondylitis (SP, ICD 10: M45, M46) with an initial biologic 
drug (etanercept, infliximab, adalimumab, golimumab) prescription (index date) 
between January 2004 and December 2013 and documented CRP levels within 
one year pre-index and one year post-index were identified and descriptively 
analyzed. Results: After the beginning of biologic drug therapy, CRP levels sig-
nificantly decreased from a mean of 17.7 mg/L before the index date to 11.7 mg/L 
after the index date (33.9% reduction, P< 0.001). In male patients, the relative 
difference in CRP levels was significantly higher than in female patients (39.0% 
versus 29.8%). The relative difference decreased with an age (49.5% in the age 
group < = 40 years, 31.4% in age group 41-50, 31.8 in age group 51-60 and 25.9 in 
age group > 60). cOnclusiOns: In this retrospective database study, performed 
among 1,695 patients with rheumatoid arthritis or spondylitis, we observed sig-
nificant reductions in CRP levels associated with male gender and younger age. 
These data have clinical relevance and significantly extend prior observational 
studies.
PMS8
cliNical EValuaTioN of aMriTadi guggulu aNd MaNdoora BhaSMa iN 
oSTEoarThriTiS PaTiENTS
Acharya S1, Singh R1, Nagappa AN2, Mateti UV2
1PG Dept. of Kayachikitsa, Muniyal Institute of Ayurveda Medical Sciences, Manipal, India, 2Dept. 
of Pharmacy Management, MCOPS, Manipal University, Manipal, India
Objectives: To compare the combined effect of Amritadi Guggulu and Mandoora 
Bhasma with Trayodashanga Guggulu in Osteoarthritis patients. MethOds: A ran-
domized single blind clinical study with pre-test and post-test design was adopted 
where the patients were given treatment for a period of one month with follow-up. 
The inclusion criterion of the patients includes Osteoarthritis of knee joints, age 
group between 30 - 60 years, either gender, and irrespective of occupation and 
habitat. A total 307 patients of osteoarthritis of knee joint were selected from 
out-patient and inpatient departments of Muniyal Ayurveda Hospital, Manipal 
and grouped into A and B 154 and 153. Group A is given Amritadi Guggulu and 
Mandoora Bhasma and Group B is given Trayodashanga Guggulu. There were 4 
dropouts in group A and 3 in group B. The outcomes were assessed by using paired 
t-test and p< 0.05 was considered as statistically significant. Results: There was 
significant relief in Joint pain (83.74%), Joint tenderness (80.33%), Joint stiffness 
(82.83%), Swelling (63.39%), Crepitus (42.26%) and restriction of movement (74.50%) 
which was statistically significant (p< 0.001 ) in group A treated with Amritadi 
Guggulu and Mandoora Bhasma. In group B treated with Trayodashanga Guggulu 
was also observed relief in in Joint pain (47.80%), Joint tenderness (78.33%), Joint 
stiffness (61.61%), Swelling (64.28%), and Crepitus (41.86%) restriction of move-
ment (60.46%) which was statistically significant (p< 0.001). In group A there was 
statistically significant improvement in TLC (15.82%), Hemoglobin (11.58%) and 
ESR (47.71%) after treatment. In group B also observed statistically significant 
improvement in TLC (14.52%), Hemoglobin (6.01%) and ESR (43.69%) after treat-
ment. cOnclusiOns: Ayurveda management with administration of Amritadi 
Guggulu and Mandoora Bhasma showed good results when compared with 
patients treated with Trayodashanga Guggulu only. There was an increase in Hb% 
and decrease in ESR in these patients.
PMS9
ThE EffEcT of SzigETVár ThErMal waTEr oN qualiTy of lifE of 
PaTiENTS wiTh rhEuMaTic diSEaSES
Hanzel A1, Molics B1, Juhász K2, Boncz I1, Ágoston I1, Varga C1
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Pécs, 
Hungary
Objectives: The thermal water of the City of Szigetvár, discovered in 1966, has a 
temperature of 62 oC when it reaches the surface and contains alkali-bicarbonatec 
with sodium chloride. The main objective is to explore the potential improvement in 
the quality of life and the effect of the thermal water as compared to warm tap water 
(placebo). It is assumed that the water with organic material content has a therapeuti-
cal effect. MethOds: Our research focuses on the therapeutic effect of this thermal 
water on patients suffering from rheumatic diseases, especially cox- and gonarthrosis, 
in a double–blind study. Sample size was n= 75. The treatment of 5 days /patient is per-
formed in Szigetvár spa in two randomly selected groups, using two tubs, and lasting 
30 minutes each time. Every patient is given tangentor and bath tub treatment alto-
gether 15 times. The methods used for the collection of data include the VAS, physical 
examination, document analysis and the Western Ontario and McMaster Universities 
Arthritis Index (WOMAC). Data were processed with the Microsoft Office Excel 2003 
and Windows SPSS 20.0 softwares, and the results were tested with the Mann-Whitney, 
the Wilcoxon and the khi-square tests. Results: Our data have shown a significant 
improvement (p= 0.035) in knee extension in the group treated with thermal water in 
contrast with the group treated with tap-water. The difference in life qualities was also 
significant measured by a Likert scale (p= 0.014). cOnclusiOns: The thermal water 
of the City of Szigetvár significantly improved the health status of patients suffering 
from rheumatic diseases in knee extension.
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antiresorptive agents against each other didn’t evidence a statistically signiﬁcant 
difference. cOnclusiOns: The results of this MTC can suggest that Risedronate, 
compared to placebo, is expected to provide the highest rate of reduction in NVF in 
women affected by postmenopausal OP. However, the mixed treatment comparisons 
among alendronate, risedronate, ibandronate, zolendronate and denosumab did not 
evidence a statistically significant difference.
PMS16
NEw PoSSiBiliTy for TESTiNg ThE dyNaMic STaBiliTy of ThE TruNk aNd 
lowEr ExTrEMiTiES
Steinhausz V1, Sió E1, Gombos G1, Bajsz V1, Tóth E2, Sömjén K3, Ács P4, Boncz I4
1University of Pécs, Zalaegerszeg, Hungary, 2Budai Physiotherapy Clinic, Budapest, Hungary, 
3Elisabet Hospital, Zirc, Hungary, 4University of Pécs, Pécs, Hungary
Objectives: The Start Excursion Balance test (SEBT) is commonly used to assess 
the dynamic stability of the trunk and lower extremities in which eight times three 
(8x3) measurements are made, this means a total of 48 measurements on the two 
sides. The aim of this research is to create a simpler and faster balance test and 
to compare this with other validated balance tests. MethOds: The study was 
implemented in August 2014 at the University of Pécs Faculty of Health Sciences 
Zalaegerszeg Training Centre in which 11 adult and 30 youth basketball players play-
ers were involved (mean age: 14.9 year, mean height: 179.9cm). The Dynamic Lateral 
Balance Test (DLBT) is based on a newly developed methodology and use a simple 
calliper to measure the values. To assess the strength of the relationship between 
the specific tests ( SEBT, Flamenco Test and DLBT) Pearson correlation coefficients 
were computed. Statistical significance was established at the α -level of 0.05 for all 
analyses, and IBM SPSS, Inc., 20.0v was used. Results: We found moderate cor-
relation between the values of the DLBT and the body height(p< 0.001), therefore we 
expressed the values correlated with body height(DLBT / body height x 100). There 
wasa moderate negative correlate between the values of the Flamenco Test and 
the DLBT test (left side: r = -0.424, p = 0.006; right side: r = -0.432, p = 0.005). There 
was a moderate positive correlation between the DLBT and the SEBT regarding 
some directions (p < 0.05), for example: right DLTB – right posteromedial: r = 0.480, 
p = 0.002; left DLBT – left posteromedial: r = 0.491, p = 0.002. cOnclusiOns: The 
present pilot study confirmed the correlation between the newly developed DLBT 
and other validated tests; consequently this new test can become a fast, simple and 
informative solution for testing the dynamic balance.
PMS17
hEalThcarE PaThwayS aNd BurdEN of diSEaSE of PaTiENTS wiTh 
PSoriaSiS aNd PSoriaTic arThriTiS
Rossi E1, Cataudella S1, Calabria S2, Rielli R1, Esposito I3, Martini N3
1CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, 2CORE, Collaborative Outcome 
Research, Bologna, Italy, 3Accademia Nazionale di Medicina, Roma, Italy
Objectives: Psoriasis and Psoriatic Arthritis (PsA) are chronic, inflammatory, 
autoimmune diseases that negatively impact on health-related quality of life. 
The aim of this study was to analyze the healthcare profile and the overall cost 
of patients with Psoriasis/PsA in the real clinical practice. MethOds: From 
ARNO Observatory database we carried out a record linkage analysis of disease 
exemptions, drug prescriptions and specialist services on 2.988.195 subjects, with 
available, complete and good quality data. Patients with Psoriasis/PsA were col-
lected from 01/01/2009 to 31/12/2011 (accrual period) and followed up to 2 years, 
to analyze specific treatments (DMARDs, biological, topical), therapy switches, 
community and hospital cares and their expenditure (mean/patient). Results: 
Of 2.988.195 subjects, 6.030 met two or more inclusion criteria (53% men, mean 
age 54,5±14,6 years). During the 2-year follow-up non-biological and biological 
drugs were prescribed respectively to 2.738 (45%) and to 902 (15%) patients. 591 
took both: 390 (66%) started DMARDs then switched to biological treatments in 7±6 
months on average. 2.783 (46%) patients received “other drugs”, mostly NSAIDs, 
Corticosteroids (systemic and dermatological use), Penicillins and Quinolone anti-
bacterials. 950 patients (16%) were discharged from ordinary and daily hospitaliza-
tions mainly for skin, connective tissue and cardiovascular (CVD) diseases. CVD 
and Neoplasia (8195€ /patient/2-year follow-up) were between the most expensive 
causes of ordinary admissions. Psychiatric disorders caused the longest stay in-
hospital (33,5 mean days/patient). 51,5% of patients received specialist healthcare 
services (blood count and liver enzymes). Patients treated with biological drugs 
were more expensive than those treated with DMARDs and topical therapies, for 
pharmaceutical, in-hospital and specialist cares (7.978€ /patient/year of follow-
up). cOnclusiOns: This assessment of healthcare profiles of patients with 
Psoriasis/PsA in the real in-hospital and community Italian settings provided 
evidence that patients treated with biological therapies are those with a more 
compromised health that induces high costs on all aspects of their care.
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characTErizaTioN of oSTEoPoroSiS iN PorTugal - TrEaTMENT 
PaTTErNS aNd rEaSoNS for uNdEr-TrEaTMENT aNd NoN-PErSiSTENcE 
wiTh PharMacological TrEaTMENTS
Rodrigues A1, Laires PA2, Gouveia N1, Eusébio M1, Canhão H3, Branco JC1
1Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, 2Merck Sharp & Dohme, Oeiras, 
Portugal, 3Faculdade de Medicina da Universidade de Lisboa, Lisbon Academic Medical Center, 
Lisbon, Portugal, Lisbon, Portugal
Objectives: The epidemiology and treatment patterns of osteoporosis are poorly 
understood in Portugal. Available evidence suggests that many post-menopausal 
(PM) women with osteoporosis are not pharmacologically treated for this condi-
tion (i.e. under-treatment). Furthermore, high levels for treatment discontinua-
tion (i.e. non-persistence) are still reported in the clinical practice. We aimed to 
describe the treatment patterns of PM osteoporosis and to understand reasons for 
under-treatment and non-persistence in Portugal. MethOds: This is an observa-
tional, cross-sectional study, nested in a patient registry database developed by the 
Portuguese Society of Rheumatology, and conducted during 2014. Complementary 
PMS13
ThE Efficacy aNd SafETy of aBaTacEPT, adaliMuMaB, ETaNErcEPT aNd 
TocilizuMaB arE coMParaBlE iN PolyarTicular JuVENilE idioPaThic 
arThriTiS
Rathi H1, Pennington B2, Amadi A3, Lister S3, Nanuwa K3
1BresMed Health Solutions, Goa, India, 2BresMed, Panaji, India, 3Bristol-Myers Squibb, Uxbridge, 
UK
Objectives: For patients with polyarticular juvenile idiopathic arthritis (pJIA), a 
published indirect comparison1 demonstrated that abatacept, adalimumab and 
etanercept are similarly efficacious, as measured by preventing disease flare after 
response to treatment. The objective of this study was to indirectly assess the effi-
cacy and safety of abatacept, adalimumab and etanercept compared to tocilizumab 
in patients with pJIA. MethOds: There have been no head-to-head trials comparing 
biological disease modifying anti-rheumatic drugs (bDMARDs) in patients with pJIA. 
A published systematic review and indirect comparison did not include tocilizumab. 
Therefore, we conducted an indirect comparison, using the Bucher method, to esti-
mate the efficacy of tocilizumab compared with the other bDMARDs. The definition 
of pJIA and baseline characteristics of patients in the tocilizumab trial were similar 
to the trials included in the published study. We also compared the incidence of 
serious adverse events (SAEs) during the double-blind phase of the trials for each 
bDMARD versus placebo using Fisher’s exact test. Results: The relative risk of 
preventing disease flare after response to treatment for abatacept, adalimumab and 
etanercept versus tocilizumab in patients with pJIA was 0.71 (95% CI: 0.35-1.43), 1.10 
(95% CI: 0.64-1.91) and 0.65 (95% CI: 0.30-1.43), respectively. The incidence of SAEs 
for each bDMARD was not significantly different when compared to placebo, with 
Fisher’s exact test p-value as 0.50, 0.49, 0.24 and 1.00, for abatacept, adalimumab, 
etanercept, and tocilizumab, respectively. cOnclusiOns: We conclude that abata-
cept, adalimumab, etanercept and tocilizumab have comparable efficacy in pJIA 
in preventing disease flare after response to treatment. The incidence of SAEs for 
each bDMARD was not statistically significantly different from that of placebo, 
and therefore was likely to be generally comparable between the bDMARDs. As the 
efficacy and safety of these bDMARDS are comparable, cost-minimisation analysis 
is an appropriate method for economic evaluation of these treatments. 1 Otten MH, 
et al. AnnRheumDis 2013;72:1806–1812
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a NETwork METaNalySiS coMPariNg ThE Efficacy of BiologicS for ThE 
TrEaTMENT of Early rhEuMaToid arThriTiS
Bizzi E1, Petrella L2, Integlia D3, Migliore A4
1San Pietro Fatebenefratelli Hsopital, rome, Italy, 2Sapienza University, Rome, Italy, 3ISHEO, Rome, 
Italy, 4S.Pietro Fatebenefratelli Hospital, rome, Italy
Objectives: Rheumatoid arthritis (RA) is a chronic disease characterized by 
inflammation of the synovial tissue leading to joint destruction. The introduction 
of biologic agents dramatically changed the prognosis of RA, especially when admin-
istered in early RA (ERA). At now there are 8 different biologic agents approved 
for the therapy of ERA. The aim of this Bayesian metanalysis is to compare and 
rank biologics indicated for ERA. MethOds: A literature search was performed 
to identify articles reporting data from RCTs on the use of biologic approved for 
ERA. MTC results are reported as the relative risk of response (RR), intended as 
the capacity of inducing an ACR20, ACR50 and ACR70 response for each biologic 
associated to MTX compared with MTX. Results: A total of 10 scientific papers 
were identified. Studies differed for length of followup and consequently only data 
at 12 weeks were taken into account. All biologic agents, associated to MTX, proved 
to be more efficacious in inducing an ACR20, ACR50 and ACR70 response respect to 
MTX. When comparing results obtained by different drugs, Etanercept proved to be 
the biologic agent that represents the best choice for obtaining ACR20 and ACR50 
response with a probability of 62,95% and 37,1% respectively, while Adalimumab 
represents the best choice for inducing ACR70 response with a probability of 
33,28%. cOnclusiOns: In our MTC on RCTs on the use of biologic agents used 
in ERA, we identified Adalimumab as the more probably best choice in obtaining 
the result of ACR70 response and for such reason this drug should be considered 
as a first line therapy in patients affected by ERA. Etanercept proved to be the more 
probably best choice in obtaining ACR50 and ACR20 response, and for such reason 
it should be considered as the second line choice in patients affected by early RA.
PMS15
MixEd TrEaTMENT coMPariSoN To raNk aNTirESorPTiVE agENTS iN 
PrEVENTiNg NEw NoN VErTEBral fracTurES iN PoSTMENoPauSal 
oSTEoPoroSiS
Massafra U1, Integlia D2, Broccoli S3, Migliore A1
1S.Pietro Fatebenefratelli Hospital, rome, Italy, 2ISHEO, Rome, Italy, 3Bioikos Pharma, Bologna, Italy
Objectives: Osteoportic non Vertebral fractures (NVF) resulted the more frequent 
kind of fracture in large population studies, with a severe incidence on annual 
costs for the health system and an increased risk of death for fractured patients. 
The burden of fracture is expected to increase with an ageing population. Data 
from head to head RCT focused on reduction of incidence of non vertebral frac-
ture among available antiresorptive agents are not availabe. This MTC aims to 
compare alendronate, risedronate, ibandronate, zolendronate and denosumab on 
completion of preventing osteoporosis NVF in a Bayesian metaanalysis assessing 
indirect comparisons. MethOds: A systematic research for RCT involving alen-
dronate, risedronate, ibandronate, zolendronate and denosumab was conducted 
using databases (CENTRAL, CINAHL,Embase, HMIC, MEDLINE and PsycINFO). MTC 
results are reported as the relative risk of response (RR), intended as the capacity 
of reducing NVF for each antiresorptive agent compared with placebo. Results: 
Nine RCTs were identiﬁed. Three trials compared Alendronate versus placebo, 2 
trials compared Risedronate vs placebo, 2 trials Zolendronate vs placebo, and one 
trial for ibandronate and denosumab. Risedronate had the highest probability (72%) 
of being the most effective treatment, followed by Zolendronate (22%), Denosumab 
(4,60%) and then alendronate (1%) and ibandronate (0.10%). Comparisons of any 
